AzTrials
AzTrials

Overweight and ObesityNCT05733871

Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet

A study testing meal replacement product- STANDARD PRODUCT and Meal replacement product- INNOVATIVE PRODUCT in people with Overweight and Obesity and Body Weight, run by Children's Hospital Srebrnjak at 1 site in Croatia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Randomized stratified controlled clinical study for evaluate the effectiveness of a diet program designed for reduce body weight through standard and innovative products that are a substitute meal for weight management in a reduction diet. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Overweight and Obesity, Body Weight
What is being tested?
meal replacement product- STANDARD PRODUCT and Meal replacement product- INNOVATIVE PRODUCT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteCroatia
Study dates
17 Jan 2023to Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • adults aged 18-60
  • both sexes
  • BMI >27 kg/m2
  • signed informed consent

Who cannot join

  • significant comorbidities: uncontrolled diabetes mellitus requiring insulin therapy and other endocrine disorders, cardiovascular disorders and other chronic diseases (including malignancies), chronic inflammatory diseases of the gastrointestinal tract, mental disorder
  • people who are currently on or have recently went through an weight loss program (in the past 3 months)
  • people who in the past 6 months had an unwanted and uncontrolled loss of body weight >5%
  • people who underwent bariatric surgery in the past 6 months.
  • people using drugs that increase or decrease appetite
  • permanent therapy with steroid drugs, antidepressants, cytostatics, hormone therapy, beta blockers, etc.
Show all 10Show fewer
  • people with eating disorders (bulimia)
  • alcohol and drug addicts
  • pregnancy, breastfeeding
  • unstable thyroid disease

Trial locations and contacts

1 site in 1 country.

Mirjana Turkalj, Prof., MD contact

+38516391164

mturkalj@bolnica-srebrnjak.hr

Croatia1 site, 1 recruiting
  • Children's Hospital Srebrnjak

    Zagreb, 10000

    Mirjana Turkalj, MD, PhD, +38516391164, mturkalj@bolnica-srebrnjak.hr

    Mirjana Turkalj, Prof,MD, PhD

    Recruiting

Other trials in Croatia

About this study

Official title: Randomized Stratified Controlled Clinical Study for Evaluate the Effectiveness of a Diet Program Designed for Reduce Body Weight Using Standard and Innovative Products

Randomized stratified controlled clinical study for evaluate the effectiveness of a diet program designed for reduce body weight through standard and innovative products that are a substitute meal for weight management in a reduction diet.

Read the detailed description

In the last few decades, there has been an increase in the number of obese people to the level of a global epidemic as a result of inadequate diet, sedentary lifestyle, but also genetic predispositions. The World Health Organization (WHO) declared obesity to be the biggest, global, chronic health problem in adults, that is increasingly becoming a more serious problem than malnutrition.On the other hand, obesity is a risk factor for the development of contemporary non-infectious diseases today that account for more than 80% of mortality in developed countries, such as vascular disease, diabetes and respiratory diseases such as asthma.

This trend is also recorded in Croatia, both in adult population and in children if the data from 2003 and 2015 are being compared, while according to data from 2019, almost two thirds of the adult population in Croatia were overweight or obese (42% overweight, 23% obese).

In cooperation with Podravka, Belupo has developed a standard and innovative product line. Products are replacing one or more one or more daily meals, and thay must comply with Regulation 2016/1413 requirements related to energy value, content and composition of fats and proteins, the amount of vitamins and minerals in this type of products.

The standard product line contains common ingredients and this type of product already exists on world markets, while the innovative product line differs from the standard one by implementing raw materials that are considered better sources of potentially bioactive components.

The study for a group of adult participants was designed in such a way that the participants in the initial stage follow a low-calorie diet of about 1000 - 1100 kcal, whereby 5 daily meals are replaced with meal replacements in the reduction diet (active group and active control) (intensive stage). In subsequent stages, subjects gradually increase their energy intake and gradually substitute meal replacement product (MRP) with regular nutritionally profiled meals (active stage and maintenance stage). The final (stable) stage represents the stage in which, in addition to one meal replacement per day, the usual meals designed by the nutritionists of Belupo and the Culinary Center of Podravka are consumed, where education and nutrition counseling is also carried out.

Study entry stage (0-2 weeks): subjects are recruited respecting the inclusion and exclusion criteria. Recruitment is carried out by a doctor. During this stage, subjects replace standard meals with meal replacement products and reduce energy intake to a final defined intake depending on the group of subjects.

36 participants in a ratio of 1:1:1

  • active group - 12
  • active control (positive control group) - 12
  • control group (negative control group) - 12

The daily energy intake is defined at around 1000-1100 kcal per day, and counseling on nutrition and physical activity is carried out.

  1. Intensive stage (2-14 weeks) about 1000 - 1100 kcal/day 5 MRP (200-220 kcal per product) + 1 salad (20 kcal per portion) + water/unsweetened tea.
  2. Active stage (14-21 weeks) 1100-1200 kcal/day 3 MRP (200-220 kcal per meal) + 2 regular meals (200-280 kcal) + water/unsweetened tea.
  3. Maintenance stage (21-28 weeks): 1200-1500 kcal/day 2 MRP (200-220 kcal per meal) + 3 regular meals (260-350 kcal) + water/unsweetened tea
  4. Stable stage (28-40 weeks): 1500-2000 kcal 1 MRP (200-220 kcal per meal) + 4 regular meals (approx. 320-450 kcal) + water/unsweetened tea Usual meals can also contain snacks with lower energy values, but it is important to consume approx. 1300-1800 kcal per day with usual foods.
Being tested
meal replacement product- STANDARD PRODUCT, Meal replacement product- INNOVATIVE PRODUCT
Keywords
nutrition, overweight, obesity, diet
Medical subject headings
Overweight, Obesity, Body Weight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • meal replacement product- STANDARD PRODUCTDietary supplement

    standard product line contains common ingredients and this type of product already exists on world markets

  • Meal replacement product- INNOVATIVE PRODUCTDietary supplement

    innovative product line contains raw materials that are considered better sources of potentially bioactive components

Study groups in NCT05733871
Study groupRoleWhat they receive
Active groupExperimentalParticipants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management
Receives: Dietary Supplement: meal replacement product- STANDARD PRODUCT
Active controlActive comparatorParticipants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
Receives: Dietary Supplement: Meal replacement product- INNOVATIVE PRODUCT
Control groupNo interventionParticipants receive personalized advice on proper nutrition for a reduction diet in which they use common food.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. BM/FM

    To determine the effectiveness of a weight change diet program based on an innovative and standard product line through actual reduction of the body mass (BM) / fat mass (FM) of the participants in relation to their pre - trial body mass(BM)/fat mass (FM).

    Measured: After 40 weeks

Secondary outcomes (3)
  1. Anthropometric measurements

    Change in anthropometric measurements- waist and hip circumference and waist/hip ratio and waist/height ratio

    Measurements of participants' waist, hip and height in meters will be taken. This multiple measurements will be aggregated and presented in ratio waist [meter] / hip [meter] and ratio waist [meter] / height [meter]

    Measured: measurements at each examination - every 2 weeks up to week 21 and every 4 weeks from week 21 to week 40

  2. Lipid profile (triglycerides, total cholesterol, HDL, LDL)

    Change of the cholesterol test/lipid panel/lipid profile (change in HDL/LDL ratio) compared to initial values

    Measured: at the beginning of the study and after 3, 6 and 9 months

  3. Questionnaire on quality of life

    The questionnaire consists of descriptive system and visual analogue scale.

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

    The visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.

    The questionnaire is in Croatian language, with a valid and accurate translation of the corresponding original document.

    Measured: at the beginning of the study (1st week) and at the end (40th week)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2023
  2. Study start17 Jan 2023
  3. Primary completionSep 2023 (estimated)
  4. Study completionDec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized stratified controlled clinical study
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05733871
Sponsor's protocol ID
KK.01.1.1.07.0075_1
Status last verified
Feb 2023
First submitted
17 Jan 2023
Last updated
17 Feb 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing meal replacement product- STANDARD PRODUCT and Meal replacement product- INNOVATIVE PRODUCT in people with Overweight and Obesity and Body Weight, run by Children's Hospital Srebrnjak at 1 site in Croatia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Croatia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mirjana Turkalj, Prof., MD (+38516391164, mturkalj@bolnica-srebrnjak.hr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

BM/FM (time frame: After 40 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in